Grifols (NASDAQ:GRFS) Stock Gets Downgrade from Zacks Research

Grifols (NASDAQ:GRFS) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday, Zacks reports.

Several other research firms have also commented on GRFS. JPMorgan Chase & Co. cut their price objective on Grifols from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, October 26th. Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, August 17th. Finally, Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. One equities research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Sell” and a consensus price target of $9.00.

Grifols Trading Up 0.6%

Shares of GRFS stock opened at $8.61 on Tuesday. Grifols has a 1-year low of $6.96 and a 1-year high of $9.77. The company has a market cap of $5.86 billion, a price-to-earnings ratio of 45.32, a PEG ratio of 0.33 and a beta of 0.75. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.33 and a quick ratio of 0.81. The stock has a 50 day simple moving average of $7.62 and a 200-day simple moving average of $8.00.

Institutional Investors Weigh In On Grifols

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GRFS. Commonwealth Equity Services LLC purchased a new stake in shares of Grifols during the third quarter worth $113,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Grifols during the 3rd quarter worth $46,000. China Universal Asset Management Co. Ltd. raised its stake in Grifols by 14.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,259 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 2,844 shares in the last quarter. Signaturefd LLC lifted its position in Grifols by 68.7% in the third quarter. Signaturefd LLC now owns 4,372 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 1,781 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its position in Grifols by 217.4% in the third quarter. Quadrant Capital Group LLC now owns 35,155 shares of the biotechnology company’s stock valued at $252,000 after acquiring an additional 24,080 shares during the last quarter.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.